All PTP4A2 reagents are produced in house and quality controlled, including 1 PTP4A2 Antibody, 32 PTP4A2 Gene, 1 PTP4A2 Protein, 2 PTP4A2 qPCR. All PTP4A2 reagents are ready to use.
Recombinant PTP4A2 proteins are expressed by E. coli with fusion tags as N-GST.
PTP4A2antibodies are validated with different applications, which are ELISA.
PTP4A2cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each PTP4A2 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
PRL-2 (Protein-tyrosine phosphatase of regenerating liver 2), also known as PTP4A2 (Protein tyrosine phosphatase type IVA, member 2), is a member of PTP family and has an important function in controlling cell growth. PRL-2 phosphatases may be multifunctional enzymes with diverse roles in a variety of tissue and cell types. The phosphatase of regenerating liver (PRL) family, comprising PRL-1, PRL-2 and PRL-3, is a group of prenylated phosphatases that are candidate cancer biomarkers and therapeutic targets. PRL-1, PRL-2, and PRL-3 represent a novel class of protein-tyrosine phosphatase with a C-terminal prenylation motif. They are three closely related intracellular enzymes that possess the PTP active site signature sequence CX 5R. The PRL-2 mRNA is elevated in primary breast tumors relative to matched normal tissue, and also dramatically elevated in metastatic lymph nodes compared with primary tumors. PRL-2 plays a role in breast cancer progression. PRL-2 is a pathogenic molecule in hematopoietic malignancies and suggest its potential as a novel therapeutic target.